18F-氟雌二醇PET显像在伏立诺他恢复内分泌敏感性II期试验中对ER阳性/HER2阴性转移性乳腺癌的应用
本II期试验纳入ER阳性/HER2阴性、既往内分泌治疗有临床获益但芳香化酶抑制剂(AI)治疗后进展的转移性乳腺癌患者,分别序贯或同时给予伏立诺他(400 mg每日)联合AI。18F-氟雌二醇PET与18F-FDG PET于基线、第2周和第8周进行。同时给药组10例可评估患者中4例获得6个月以上无进展临床获益;基线18F-氟雌二醇摄取较高与更长无进展生存相关,伏立诺他未在18F-氟雌二醇PET检测水平改变ER表达。
要点
- 同时给予伏立诺他与AI在AI耐药患者中10例可评估者4例获6个月以上无进展。
- 基线18F-氟雌二醇PET摄取较高与更长无进展生存相关。
- 伏立诺他未在18F-氟雌二醇PET检测水平系统性增加ER雌二醇结合。
核心结论
- 同时给予HDACI与AI在单用AI耐药的乳腺癌患者中显示临床获益,10例可评估患者中4例获6个月以上无进展。
- 较高的基线18F-氟雌二醇PET摄取可识别可能从联合治疗中获益的患者,但伏立诺他未在18F-氟雌二醇PET检测水平改变ER表达。
研究设计与样本
- II期试验纳入ER阳性/HER2阴性、既往内分泌治疗有临床获益但后来AI治疗进展的转移性乳腺癌患者。
- 8例序贯给予伏立诺他(400 mg每日)联合AI,随后15例同时给予伏立诺他(400 mg每日)联合AI。
- 于基线、第2周和第8周行18F-氟雌二醇PET与18F-FDG PET扫描。
主要发现
- 8例序贯治疗,15例同时治疗;8例在第8周疾病稳定,其中6例疾病稳定超过6个月。
- 较高的基线18F-氟雌二醇摄取与更长无进展生存相关。
- 18F-氟雌二醇摄取未随伏立诺他暴露系统性增加,提示区域ER雌二醇结合无变化。
- 18F-FDG摄取未见显著下降,而肿瘤消退时预期可见该下降。
- 同时给药组10例可评估患者中4例获6个月以上无进展。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Histone deacetylase inhibitors (HDACIs) may overcome endocrine resistance in estrogen receptor-positive (ER+) metastatic breast cancer. We tested whether 18F-fluoroestradiol PET imaging would elucidate the pharmacodynamics of combination HDACIs and endocrine therapy. Methods: Patients with ER+/human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer with prior clinical benefit from endocrine therapy but later progression on aromatase inhibitor (AI) therapy were given vorinostat (400 mg daily) sequentially or simultaneously with AI. 18F-fluoroestradiol PET and 18F-FDG PET scans were performed at baseline, week 2, and week 8. Results: Eight patients were treated sequentially, and then 15 simultaneously. Eight patients had stable disease at week 8, and 6 of these 8 patients had more than 6 mo of stable disease. Higher baseline 18F-fluoroestradiol uptake was associated with longer progression-free survival. 18F-fluoroestradiol uptake did not systematically increase with vorinostat exposure, indicating no change in regional ER estradiol binding, and 18F-FDG uptake did not show a significant decrease, as would have been expected with tumor regression. Conclusion: Simultaneous HDACIs and AI dosing in patients with cancer resistant to AI alone showed clinical benefit (6 or more months without progression) in 4 of 10 evaluable patients. Higher 18F-fluoroestradiol PET uptake identified patients likely to benefit from combination therapy, but vorinostat did not change ER expression at the level of detection of 18F-fluoroestradiol PET.
引用
- Peterson LM, Kurland BF, Yan F, et al. 18F-Fluoroestradiol PET Imaging in a Phase II Trial of Vorinostat to Restore Endocrine Sensitivity in ER+/HER2- Metastatic Breast Cancer. J Nucl Med. 2020. PMID: 32591490. doi:10.2967/jnumed.120.244459
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。